Company profile

Mochi Health

A subscription-based telehealth platform offering weight care and a broader menu including skin, hair, mental-health and menopause services. Membership, medication and diagnostics are separate charges; an August 2026 notice changed compounded medication pricing from flat rates to variable tiers.

By Inside Telehealth Editorial

Operating status: Operating
Updated: September 8, 2026

Facts were checked against the primary sources listed on this page as of the date shown. This profile reports publicly documented facts; it makes no clinical claims and does not rate clinical quality or recommend treatment. How we research

On this page

StatusOperating

SizeNot verified

Founded2022

HeadquartersNot verified

At a glance

Key answers

What does Mochi Health offer?: Weight care, Dermatology, Hair loss, Mental health, Women's health, Sexual health
How is care delivered?: Hybrid
How can patients access it?: Direct to consumer
How does payment work?: Cash pay, Insurance Insurance participation can vary by service and plan; confirm coverage with the provider.
What does it cost?: Standard monthly membership $79; advertised first-month promotion $39 with restrictions. The August 2026 notice lists two compounded products at $60–$99 and $90–$199 per company-labeled month, additional to membership. Those are not prices for its whole catalog: brand-name and other products have separate quotes, and diagnostics are extra.
Where is it available?: Nationwide Availability source ↗
Who owns it?: Company materials name Myra Ahmad, MD, as founder and CEO. The website identifies Mochi Health Corp. as the administrative/technology business supporting independently owned professional practices. A current ownership breakdown was not established.
When was this profile checked?: September 8, 2026 · See sources

Visit official website ↗

What Mochi Health does

Mochi Health connects subscribers with clinicians and ongoing support. Its current menu extends beyond weight management to skin, hair, mental health, menopause and sexual-health offerings. The site describes physician access, coaching and messaging, with prescribed products supplied through pharmacies. Pharmacy relationships and the Aequita proceeding are discussed below.

The site’s corporate disclaimer identifies Mochi Health Corp. as the administrative and technology business, not the provider of professional medical services. Those services are described as coming from independently owned practices.

Mochi advertises compounded semaglutide and tirzepatide among its products. FDA’s compounded-drug marketing explanation distinguishes these products from approved generic drugs. This profile reports the service and its charges, not clinical equivalence, effectiveness or individual eligibility for a compounded prescription.

History and organization

A company account states that Mochi was founded in 2022 and names Myra Ahmad as founder and CEO. It does not establish the current equity ownership breakdown.

A June 2026 app announcement describes the addition of Spanish-language app access and again identifies Ahmad as founder and CEO. An app-language feature should not be read as guaranteed availability of a Spanish-speaking clinician for every appointment.

Joining and service availability

The FAQ describes video visits and nutrition/wellness support, and says the service can be accessed across the United States. It distinguishes the regular subscription from Wellness Plus, an option for people with qualifying insurance.

The terms describe both paid and limited free membership. Free access excludes one-to-one video visits and can exclude categories of care or products. A nationwide headline, account registration or insurance submission does not guarantee program eligibility, pharmacy supply or a prescription. We did not enroll or test appointment availability.

Membership and medication prices

The homepage advertises a $79 standard monthly membership and a $39 introductory month for new subscribers. It expressly excludes medication and diagnostic charges. The promotion terms, effective January 20, 2026, exclude previous subscribers and Wellness Plus, and provide for automatic billing at the standard selected-plan rate after the promotion. The homepage also says the offer is unavailable in some states.

The company’s August 2026 pricing update is important when reading older price references:

Medication charge	Published range per company-labeled month	What can change it
Compounded semaglutide	$60–$99	Prescribed tier, state and dispensing pharmacy
Compounded tirzepatide	$90–$199	Prescribed tier, state and dispensing pharmacy

These charges are in addition to membership, and the update describes the posted rates as representative. The account’s upcoming order quote may differ. The lower endpoint is not the price for every patient, and these two compounded products do not represent the price of brand-name medication or the rest of Mochi’s catalog.

The FAQ still describes $99 and $199 as flat prices for all tiers, despite the newer update. It also publishes prepaid membership choices. Confirm the selected plan’s actual upfront charge and renewal amount; we have not converted a promotional or prepaid option into an apparently commitment-free monthly price.

Cancellation, renewals and refunds

The terms distinguish cancelling membership from changing or cancelling a medication subscription. Paid membership cancellation takes effect at the end of its term. A medication order must be changed before its refill request is sent to a pharmacy; cancelling membership also cancels medication subscriptions that require it.

Partly used membership periods are generally not refundable. Discretionary exceptions are limited, including no discretionary membership refund for a month in which provider services were received. Medication fees are not refundable after an order is sent for dispensing. The shorter refund page also says prescription sales are final and directs people to contact support about filling errors. “Cancel anytime” does not mean every past or already-processed charge is reversible.

Legal history

An earlier Northern District of California listing, checked September 8, 2026, recorded an August 4, 2025 filing for Novo Nordisk A/S et al. v. Mochi Health Corp. et al., case 5:25-cv-06563-EKL. The current GovInfo case metadata categorizes the case as a trademark matter and links the September 3, 2026 discovery order. The original filing date comes from the earlier listing, not the current GovInfo metadata. These records establish a proceeding and a procedural order, not a finding of infringement or other liability or a final outcome.

In a separate Lilly case, 3:25-cv-03534-JSC, the April 20, 2026 court order allowed unfair-competition and false-advertising claims to proceed, but dismissed the conspiracy claim with permission to amend it. Lilly challenges compounded-product marketing and alleged control over clinical decisions. Mochi’s defendants disputed those claims, including whether the alleged conduct went beyond administrative services. This was a pleading-stage ruling, not a finding that the alleged conduct occurred. Mochi’s public response frames the litigation as a dispute over affordable access and says its platform supports physician autonomy.

The Lilly order also recounts allegations of shared control involving Mochi and Aequita Pharmacy; this profile does not treat those allegations as a verified ownership chart. Separately, Washington’s pharmacy commission announced a limited stop-service action against Aequita on March 13, 2025, citing alleged failures involving staff qualifications, supervision and sterile-compounding procedures. The notice restricted Aequita’s compounding and distribution of compounded products in Washington pending resolution. It was an action against the pharmacy, not a shutdown order against Mochi. A current resolution has not been verified here.

Privacy and evidence limits

The privacy policy distinguishes platform information from protected health information held by affiliated practices, whose separate notice governs that information. It describes advertising-related processing and other platform uses. This is a report of the policy, not a security or data-flow audit.

Prices and product availability are particularly variable here. We have not tested fulfillment, audited pharmacies or independently verified the site’s patient counts. Readers should confirm the exact plan and pharmacy quote before paying.

Mochi Health medication prices

Published monthly pricing and cost components for Mochi Health's named medication programs, from the national medication guides. These are advertised prices, not a quote; availability in a particular state is shown in the state guides. Each product is labelled as one of three presentations: an advertised monthly bundle, a known monthly subtotal (not a final bill), or a record where dose-level totals are not disclosed, which may give only a starting figure or cost components such as a membership.

Compounded semaglutide · injection

Known monthly subtotal—not a confirmed all-in total

0.22 mg/week: $139/mo
0.44 mg/week: $149/mo
0.88 mg/week: $161/mo
1.5 mg/week: $171/mo
2.21 mg/week: $175/mo
2.67 mg/week: $178/mo

Includes the $79/month membership in each figure above. Compounded injection and monthly membership with physician and care-team access, in-app coaching and messaging. The FAQ says shipping is included in the medication prices.

Not priced: The membership excludes medications and diagnostic services; diagnostic services are not priced here. The guide says the account shows the exact price for the prescribed dose and pharmacy, which may differ.

Billing and introductory offers

The August 2026 guide prices each weekly dose per vial labeled as one month and calls these representative rates that vary by prescribed dose, state and pharmacy. These are medication prices; membership is billed separately. Figures use the $79 monthly membership, not a prepaid plan.

Eligible new subscribers pay $39 membership for the first month, reducing each subtotal by $40. The page says promotional pricing is not available in all states.

Price check: September 23, 2026. Mochi Health — New Per-Dose Pricing: What Changed · Mochi Health — services and membership · Mochi Health — FAQ

Compounded tirzepatide · injection

Known monthly subtotal—not a confirmed all-in total

2.2 mg/week: $169/mo
4.4 mg/week: $198/mo
6.6 mg/week: $223/mo
8.8 mg/week: $253/mo
11.24 mg/week: $263/mo
13.2 mg/week: $273/mo
16.6 mg/week: $278/mo

Billing and introductory offers

Eligible new subscribers pay $39 membership for the first month, reducing each subtotal by $40. The page says promotional pricing is not available in all states.

Price check: September 23, 2026. Mochi Health — New Per-Dose Pricing: What Changed · Mochi Health — services and membership · Mochi Health — FAQ

Full details: GLP-1 medication access guide · Semaglutide guide · Tirzepatide guide · Official site ↗

Across the directory

Explore Mochi Health across Inside Telehealth

These links point to currently published guides that include Mochi Health. They organize existing evidence; they do not add a recommendation or establish that every service is available everywhere.

Care-area guides

Weight care

Medication-access guides

State directories

Browse 50 state directories

Availability claims

One row per jurisdiction and reported status. Scopes that share a status, attribution, source and observation date are listed together in a single row; a scope the company reports differently keeps its own row. "Company / platform" means the company as a whole, not every service. "Company-reported" means the company said it; it has not been independently checked unless the attribution says so. Read each row's note.

Availability claims for Mochi Health
Jurisdiction	Scope	Status	Attribution	Observed	Source
Arizona (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Arizona Telehealth Platform Online, Mochi Health
Mochi's Arizona state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page explicitly lists both among injectable medications. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Arizona or legal clearance for an order.
Colorado (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Colorado Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Colorado state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Colorado state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Colorado or legal clearance for an order.
Florida (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Florida Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Florida state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Florida state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Florida or legal clearance for an order.
Georgia (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Georgia Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Georgia state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Georgia state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Georgia or legal clearance for an order.
Illinois (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Illinois Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Illinois state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page does not mention an oral compounded product, so the injectable form is inferred from the product name rather than stated. Compounded tirzepatide: Mochi's Illinois state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Illinois or legal clearance for an order.
Maryland (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Maryland Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Maryland state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Maryland state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Maryland or legal clearance for an order.
Massachusetts (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Massachusetts Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Massachusetts state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page does not mention an oral compounded product, so the injectable form is inferred from the product name rather than stated. Compounded tirzepatide: Mochi's Massachusetts state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Massachusetts or legal clearance for an order.
Minnesota (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Minnesota Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Minnesota state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page does not mention an oral compounded product, so the injectable form is inferred from the product name rather than stated. Compounded tirzepatide: Mochi's Minnesota state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Minnesota or legal clearance for an order.
New York (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — New York Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's New York state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's New York state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in New York or legal clearance for an order.
Oregon (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Oregon Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Oregon state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page does not mention an oral compounded product, so the injectable form is inferred from the product name rather than stated. Compounded tirzepatide: Mochi's Oregon state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Oregon or legal clearance for an order.
Pennsylvania (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Pennsylvania Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Pennsylvania state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Pennsylvania state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Pennsylvania or legal clearance for an order.
Rhode Island (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Rhode Island Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Rhode Island state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Rhode Island state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Rhode Island or legal clearance for an order.
United States	Weight care	Available	Company-reported	September 11, 2026	Mochi Health — FAQ, Mochi Health
Mochi says its telehealth platform can be used from anywhere in the United States, and weight care is the service it sells, so the paid membership and its physician visits are offered nationwide. The company separately states that medication availability and pricing vary by state, and publishes no state list for either, so a state listed here does not mean a particular compounded or branded medicine can be prescribed or shipped to you there. Membership, medication and diagnostics are billed separately. This is the company's own description of its service, not a booked appointment, confirmed insurance, individual eligibility, or a guarantee that any prescription will be issued.
United States	Company / platform	Limited	Company-reported	September 8, 2026	Mochi Health — FAQ, Mochi Health
FAQ reports U.S.-wide service access. Program, clinician, pharmacy, insurance and promotional eligibility remain separate; no individual enrollment or all-product state verification.
United States	Compounded semaglutide Compounded tirzepatide	Unknown	Company-reported	September 23, 2026	Mochi Health — Medications, Mochi Health
The company states that medication availability and pricing vary by state and publishes no state list. A separate notice limits a promotional membership rate rather than access. Confirm this medication is available in your state, and at what price, before paying. Since September 23, 2026, separate state pages name this product for Arizona, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota, New York, Oregon, Pennsylvania, Rhode Island, Virginia and Washington; those states have their own records, and this record covers the remaining states.
Virginia (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Virginia Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Virginia state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page lists compounded oral semaglutide separately. Compounded tirzepatide: Mochi's Virginia state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Virginia or legal clearance for an order.
Washington (US)	Compounded semaglutide Compounded tirzepatide	Available	Company-reported	September 23, 2026	Mochi Health — Washington Telehealth Platform Online, Mochi Health
Compounded semaglutide: Mochi's Washington state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. The page does not mention an oral compounded product, so the injectable form is inferred from the product name rather than stated. Compounded tirzepatide: Mochi's Washington state page, answering which weight loss medications it offers there, names compounded semaglutide and tirzepatide among its compounded medication options. This is an advertised compounded product, not a branded or FDA-approved generic offer. The company's medications page separately says availability and pricing vary by state. The page does not establish pharmacy stock, the dispensing pharmacy, clinician approval, individual eligibility, the price in Washington or legal clearance for an order.

Timeline

Dated, sourced events. Each date is shown at the precision the source supports; "alleged" means a claim in a filing, not a finding.

April 20, 2026 (issued) — Lilly claims partly survive dismissal motion Litigation
The court allowed unfair-competition and false-advertising claims to proceed while dismissing conspiracy with leave to amend. Defendants contested the allegations; no liability determination was made. Status: Pending as of September 8, 2026; Primary-source verified. Source: Lilly v. Mochi — order on motion to dismiss the amended complaint (+1 more in Sources)
August 4, 2025 (filed) — Novo Nordisk litigation filed Litigation
Court listing categorizes the case as a trademark matter and records a September 2026 discovery order, not a merits ruling. Status: Pending as of September 8, 2026; Primary-source verified. Source: Novo Nordisk A/S et al. v. Mochi Health Corp. et al. — case metadata and September 3, 2026 discovery order
March 13, 2025 (reported) — Washington announces action against Aequita Pharmacy Regulatory action
Washington announced a limited stop-service action against Aequita over alleged compounding-practice deficiencies. The order concerned the pharmacy, not Mochi itself; present resolution has not been verified. Status: Current status unknown as of September 8, 2026; Primary-source verified. Source: Washington pharmacy commission announces limited stop-service action against Aequita (+1 more in Sources)

Sources

Consolidated bibliography for this profile: every record cited in the text or behind its structured data, listed once.

Mochi Health — services and membership — Mochi Health; Company document; accessed September 23, 2026 — Current marketing menu and introductory versus regular membership. Medication and diagnostics excluded; selected prepaid-plan totals require confirmation.
Mochi Health — FAQ — Mochi Health; Company document; accessed September 23, 2026 — The September 15, 2026 FAQ describes dose-dependent medication pricing, membership options and insurance distinctions. Shipping is advertised included; diagnostic services and possible charges under the terms require a separate quote.
Mochi Health — New Per-Dose Pricing: What Changed — Mochi Health; Company document; accessed September 23, 2026 — August 2026 change to variable medication charges. Rates are representative and pharmacy, state and account quotes can differ.
Mochi Health — Terms of Use, updated July 10, 2026 — Mochi Health; Company document; Revised July 10, 2026; accessed September 8, 2026 — Paid/free membership, medication subscriptions, cancellation cutoffs and refund exceptions. Corporate-name spelling differs slightly from the site footer.
Mochi Health — Discount Promotion Terms, effective January 20, 2026 — Mochi Health; Company document; Effective January 20, 2026; accessed September 8, 2026 — First-time subscriber restrictions; excludes medication and Wellness Plus; recurring billing after promotional period.
Mochi Health — Refunds and Returns — Mochi Health; Company document; accessed September 8, 2026 — Prescription sales final, with support contact for suspected filling errors; membership refund rules are in the general terms.
Mochi Health — Privacy Policy — Mochi Health; Company document; accessed September 8, 2026 — Platform privacy policy distinguishes affiliated-practice protected health information and its separate notice; not independently audited behavior.
Mochi Health — company milestone announcement — Mochi Health; Company document; accessed September 8, 2026 — Company-reported 2022 founding and founder Myra Ahmad. Publication/revision labels differ from the embedded dateline.
Mochi Health — Spanish-language app announcement — Mochi Health; Company document; accessed September 8, 2026 — Company describes a Spanish-language app experience; not a guarantee of every clinician's language or availability.
FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs — U.S. Food and Drug Administration; Regulator document; accessed September 8, 2026 — General explanation of compounded-product marketing and the distinction from approved generic drugs. Company-specific regulatory actions are separate records.
Novo Nordisk A/S et al. v. Mochi Health Corp. et al. — case metadata and September 3, 2026 discovery order — U.S. District Court, Northern District of California (via GovInfo); Court record; accessed September 11, 2026 — GovInfo's metadata categorizes case 5:25-cv-06563 as a trademark matter and links the September 3, 2026 order on in-house counsel access to AEO information. The earlier court listing, checked September 8, 2026 at https://cand.uscourts.gov/cases-e-filing/cases/525-cv-06563-ekl/novo-nordisk-et-al-v-mochi-health-corp-et-al, recorded an August 4, 2025 filing date; that URL returned 404 on September 11, 2026. The original filing date is historical listing evidence, not a date supplied by the current GovInfo metadata. The discovery order is not a determination of liability.
Lilly v. Mochi — order on motion to dismiss the amended complaint — U.S. District Court, Northern District of California (copy hosted by Justia); Court record; Filed April 20, 2026; accessed September 8, 2026 — Case 3:25-cv-03534-JSC, document 126. Pleading-stage ruling permits two claims to proceed and dismisses conspiracy with leave to amend; allegations are not findings of fact.
Mochi — response to Lilly litigation — Mochi Health; Company document; Revised July 31, 2026; accessed September 8, 2026 — Company's position on the litigation. Displayed publication and revision labels are not the lawsuit's filing date.
Washington pharmacy commission announces limited stop-service action against Aequita — Washington State Department of Health; Regulator document; Published March 13, 2025; accessed September 8, 2026 — Release 25-034 concerns Aequita Pharmacy LLC, credential PHAR.CF.61458335. It describes an action pending resolution, not the pharmacy's verified present status or an order against Mochi.
Mochi Health — Arizona Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Arizona names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Colorado Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Colorado names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Florida Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Florida names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Georgia Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Georgia names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Illinois Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Illinois names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Maryland Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Maryland names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Massachusetts Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Massachusetts names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Minnesota Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Minnesota names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — New York Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in New York names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Oregon Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Oregon names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Pennsylvania Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Pennsylvania names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Rhode Island Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Rhode Island names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Medications — Mochi Health; Company document; accessed September 11, 2026 — Product listing for the company's compounded and branded weight-management medications. Carries the statement that medication availability and pricing vary by state, which is separate from the promotional-pricing footnote limiting a membership rate rather than access.
Mochi Health — Virginia Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Virginia names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.
Mochi Health — Washington Telehealth Platform Online — Mochi Health; Company document; accessed September 23, 2026 — State landing page. Its answer on which weight loss medications Mochi offers in Washington names compounded semaglutide and tirzepatide alongside branded products. The page is undated. It names prescribing options, not stock, eligibility, price or pharmacy fulfilment.